- Report
- January 2024
- 200 Pages
Global
From €4797EUR$5,000USD£4,132GBP
- Drug Pipelines
- November 2023
- 30 Pages
Global
From €3118EUR$3,250USD£2,686GBP
- Report
- April 2021
- 51 Pages
Global
€1265EUR$1,318USD£1,089GBP
- Report
- January 2019
- 16 Pages
Global
From €9595EUR$10,000USD£8,264GBP
- Report
- April 2023
- 260 Pages
Global
From €3454EUR$3,600USD£2,975GBP
- Report
- June 2019
- 147 Pages
Global
From €10550EUR$10,995USD£9,086GBP
Calquence (acalabrutinib) is a prescription medication used to treat certain types of B-cell non-Hodgkin lymphoma (NHL). It is a Bruton's tyrosine kinase (BTK) inhibitor, which works by blocking the activity of BTK, a protein that helps B-cells grow and divide. Calquence is approved for use in combination with other medications to treat adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. It is also approved for use as a monotherapy to treat adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
The Calquence market is a rapidly growing segment of the lymphoma drug market. It is a highly competitive market, with several companies offering similar products. Companies in the Calquence market include AstraZeneca, AbbVie, Gilead Sciences, and Janssen Pharmaceuticals. Show Less Read more